Shattuck Labs reports FY2025 net loss $48.8M; SL-325 Ph1 data expected Q2 2026

Shattuck Labs, Inc.

Net loss for FY2025 was $48.8M ($0.70/diluted share), vs $75.4M ($1.49) in FY2024.
Cash and investments at Dec 31, 2025 were $78.1M; after $21.4M ATM raise in Q1 2026, pro forma cash ~$94.5M.
SL-325 Phase 1 in healthy volunteers nearly complete; data expected Q2 2026, Phase 2 in Crohn's planned Q3 2026.
R&D expenses fell to $35.3M from $67.2M, driven by discontinuation of SL-172154 program.
Michael Choi, M.D., appointed VP of Clinical Development; cash runway guidance extended into 2029.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.